For the year ending 2025-12-31, BRNS had -$40,548K decrease in cash & cash equivalents over the period. -$48,016K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -66,458 |
| Share based compensation | 468 |
| Impairment of long-lived assets | 5,794 |
| Impairment of goodwill | 0 |
| Depreciation and amortization | 5,845 |
| Non-cash lease expenses | 3,332 |
| Unrealized foreign exchange loss | -3,742 |
| Change in contingent consideration | 26 |
| Non-cash interest expense | 51 |
| Deferred tax benefit | -175 |
| Profit on sale of property and equipment | 245 |
| Prepaid expenses and other current assets | -1,704 |
| Research and development incentives receivable | -6,417 |
| Accounts payable | -2,202 |
| Accrued expenses and other current liabilities | -3,793 |
| Deferred income | -506 |
| Operating lease liabilities | -1,979 |
| Net cash used in operating activities | -47,979 |
| Proceeds from sale of property and equipment | 453 |
| Purchases of property and equipment | 37 |
| Net cash provided by/(used) in investing activities | 416 |
| Issue of shares from the exercise of stock options | 2 |
| Proceeds from issue of ordinary shares, net of issuance costs | 0 |
| Net cash provided by financing activities | 2 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 7,013 |
| Net decrease in cash, cash equivalents and restricted cash | -40,548 |
| Cash, cash equivalents and restricted cash, beginning of the period | 112,400 |
| Cash, cash equivalents and restricted cash, end of the period | 71,852 |
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)